StudyID,Drug_Name,Arm_ID,Endpoint_Name,Endpoint_Type,Strategy,EP_P_value,Missing_Imput,Covariate_Adjust,MCP,Subgroup_Ana,EP_Value,EP_Unit,EP_Point,ARR,NNT,EP_95CI,Med_OS,OS_YrX,Med_PFS,ORR,pCR,Med_DOR,RMST,PRO,QoL,endpoint_group_id,endpoint_group_title_raw,endpoint_group_desc_raw,endpoint_group_title_norm,endpoint_group_desc_norm,matched_arm_id,arm_group_title_raw,arm_group_desc_raw,arm_group_title_norm,arm_group_desc_norm,match_type,title_score,desc_score,debug_notes,top_candidates_json
NCT00387465,Entinostat; Azacitidine 40mg/m2,NCT00387465_A3,(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT),Primary,,[],,,,,[],,"[{""effect"": {""type"": ""Maximum Tolerated Dose"", ""value"": ""40""}}]",,,[],,,,,,,,,,O1,Phase II Arm,Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.,phase ii arm,patients receive azacitidine 40mg m2 subcutaneously sq on days 1 6 and 8 10 and entinostat 7mg po on days 3 and 10 treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity,NCT00387465_A3,Phase II Arm,Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.,phase ii arm,patients receive azacitidine 40mg m2 subcutaneously sq on days 1 6 and 8 10 and entinostat 7mg po on days 3 and 10 treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity,precise_title,100,100,,"[{""arm_id"": ""NCT00387465_A3"", ""arm_group_title_raw"": ""Phase II Arm"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00387465_A2"", ""arm_group_title_raw"": ""Phase I - 40mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 46, ""desc_score"": 59}, {""arm_id"": ""NCT00387465_A1"", ""arm_group_title_raw"": ""Phase I - 30mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 46, ""desc_score"": 58}]"
NCT00387465,Azacitidine 30mg/m2; Entinostat,NCT00387465_A1,(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT),Primary,,[],,,,,"[{""measure_title"": ""(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O2"", ""value"": ""0""}]}]",Participants,"[{""effect"": {""type"": ""Maximum Tolerated Dose"", ""value"": ""40""}}]",,,[],,,,,,,,,,O2,Phase I - 30mg/m2 Azacitidine,Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.,phase i 30mg m2 azacitidine,patients receive azacitidine 30mg m2 sq and entinostat 7mg po on days 3 and 10 of each cycle,NCT00387465_A1,Phase I - 30mg/m2 Azacitidine,Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.,phase i 30mg m2 azacitidine,patients receive azacitidine 30mg m2 sq and entinostat 7mg po on days 3 and 10 of each cycle,precise_title,100,100,,"[{""arm_id"": ""NCT00387465_A1"", ""arm_group_title_raw"": ""Phase I - 30mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00387465_A2"", ""arm_group_title_raw"": ""Phase I - 40mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT00387465_A3"", ""arm_group_title_raw"": ""Phase II Arm"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."", ""title_score"": 46, ""desc_score"": 32}]"
NCT00387465,Entinostat; Azacitidine 40mg/m2,NCT00387465_A2,(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT),Primary,,[],,,,,"[{""measure_title"": ""(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O3"", ""value"": ""0""}]}]",Participants,"[{""effect"": {""type"": ""Maximum Tolerated Dose"", ""value"": ""40""}}]",,,[],,,,,,,,,,O3,Phase I - 40mg/m2 Azacitidine,Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.,phase i 40mg m2 azacitidine,patients receive azacitidine 40mg m2 sq and entinostat 7mg po on days 3 and 10 of each cycle,NCT00387465_A2,Phase I - 40mg/m2 Azacitidine,Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.,phase i 40mg m2 azacitidine,patients receive azacitidine 40mg m2 sq and entinostat 7mg po on days 3 and 10 of each cycle,precise_title,100,100,,"[{""arm_id"": ""NCT00387465_A2"", ""arm_group_title_raw"": ""Phase I - 40mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00387465_A1"", ""arm_group_title_raw"": ""Phase I - 30mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT00387465_A3"", ""arm_group_title_raw"": ""Phase II Arm"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."", ""title_score"": 46, ""desc_score"": 33}]"
NCT00387465,,NCT00387465_A3,(Phase II) Objective Response Rate After Treatment With Azacitidine and Entinostat as Assessed by Number of Participants With Response After at Least One Cycle of Therapy,Primary,,[],,,,,"[{""measure_title"": ""(Phase II) Objective Response Rate After Treatment With Azacitidine and Entinostat as Assessed by Number of Participants With Response After at Least One Cycle of Therapy"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O1"", ""value"": ""1""}, {""group_id"": ""O1"", ""value"": ""22""}, {""group_id"": ""O1"", ""value"": ""1""}, {""group_id"": ""O1"", ""value"": ""10""}]}]",Participants,[],,,[],,,,,,,,,,O1,Azacitidine 40mg/m2 With Entinostat,Patients receive azacitidine 40mg/m2 SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.,azacitidine 40mg m2 with entinostat,patients receive azacitidine 40mg m2 sc on days 1 6 and 8 10 and entinostat po on days 3 and 10 treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity,NCT00387465_A3,Phase II Arm,Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.,phase ii arm,patients receive azacitidine 40mg m2 subcutaneously sq on days 1 6 and 8 10 and entinostat 7mg po on days 3 and 10 treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity,fuzzy_desc,17,95,,"[{""arm_id"": ""NCT00387465_A3"", ""arm_group_title_raw"": ""Phase II Arm"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."", ""title_score"": 17, ""desc_score"": 95}, {""arm_id"": ""NCT00387465_A2"", ""arm_group_title_raw"": ""Phase I - 40mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 35, ""desc_score"": 60}, {""arm_id"": ""NCT00387465_A1"", ""arm_group_title_raw"": ""Phase I - 30mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 35, ""desc_score"": 59}]"
NCT00387465,,NCT00387465_A3,Effect of Entinostat and Azacitidine on DNA Methylation and Response,Key Secondary,,[],,,,,"[{""measure_title"": ""Effect of Entinostat and Azacitidine on DNA Methylation and Response"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O1"", ""value"": ""8""}]}]",Participants,[],,,[],,,,,,,,,,O1,Azacitidine 40mg/m2 With Entinostat,Patients receive azacitidine 40mg/m2 SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.,azacitidine 40mg m2 with entinostat,patients receive azacitidine 40mg m2 sc on days 1 6 and 8 10 and entinostat po on days 3 and 10 treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity,NCT00387465_A3,Phase II Arm,Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.,phase ii arm,patients receive azacitidine 40mg m2 subcutaneously sq on days 1 6 and 8 10 and entinostat 7mg po on days 3 and 10 treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity,fuzzy_desc,17,95,,"[{""arm_id"": ""NCT00387465_A3"", ""arm_group_title_raw"": ""Phase II Arm"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."", ""title_score"": 17, ""desc_score"": 95}, {""arm_id"": ""NCT00387465_A2"", ""arm_group_title_raw"": ""Phase I - 40mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 35, ""desc_score"": 60}, {""arm_id"": ""NCT00387465_A1"", ""arm_group_title_raw"": ""Phase I - 30mg/m2 Azacitidine"", ""arm_group_desc_raw"": ""Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle."", ""title_score"": 35, ""desc_score"": 59}]"
